The authors also highlight that TKa provides unique information that may complement ctDNA. While ctDNA provides important genomic information about tumor mutations and clonal evolution, TKa provides a ...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that six clinical abstracts demonstrating the broad use of its NeXT Personal® test will be ...
With the help of DNA testing company Natera and its personalized molecular residual disease (MRD) blood test Signatera, Roche ...
Association of plasma tumor DNA (ptDNA) with increased risk of venous thromboembolism (VTE) in metastatic castration resistant prostate cancer patients (mCRPC). An open-label, pharmacokinetic study to ...
SAN FRANCISCO — A blood test that measures circulating tumor DNA (ctDNA) can help to identify those patients with resectable colorectal cancer who are most likely to derive the most benefit from ...
Please provide your email address to receive an email when new articles are posted on . Approximately 25% of patients had ctDNA- or imaging-confirmed recurrence. More than 30% had evidence of ...
DNA liquid biopsies detect breast cancer at molecular levels to guide personalized therapy and monitor for recurrence or progression. For many patients diagnosed with early-stage breast cancer, the ...
This transcript has been edited for clarity. Cheryl Lee, MD: Welcome to Medscape InDiscussion. I'm Dr Cheryl Lee. Today we'll be talking about circulating tumor DNA, or ctDNA, testing as the next step ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results